Skip to main content

Bender Jeremy's Form 4 filing

Day One Biopharmaceuticals, Inc.DAWN · filed May 17, 2024

Accession no.
0001415889-24-013620
Filed
May 17, 2024
Trade date
May 15-16, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $126.6K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bender JeremyCIK 0001863107Director, Officer (CHIEF EXECUTIVE OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 15, 2024Common StockMOption exerciseAcquired+3,562–F1–646,164Direct
May 15, 2024Common StockMOption exerciseAcquired+4,750–F1–650,914Direct
May 15, 2024Common StockMOption exerciseAcquired+11,687–F1–662,601Direct
May 16, 2024Common StockSSaleDisposed−7,873$16.08−$126,597.84654,728Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 15, 2024Common StockMOption exerciseDisposed−3,562$0.00$021,380Direct
May 15, 2024Common StockMOption exerciseDisposed−4,750$0.00$047,500Direct
May 15, 2024Common StockMOption exerciseDisposed−11,687$0.00$0163,626Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)